TY  - JOUR
AU  - Schlenk, Richard
TI  - Genetics as predictive marker for consolidation therapy with high-dose cytarabine in acute myeloid leukemia.
JO  - Haematologica
VL  - 109
IS  - 6
SN  - 0390-6078
CY  - Pavia
PB  - Ferrata Storti Foundation
M1  - DKFZ-2024-01192
SP  - 1629 - 1630
PY  - 2024
N1  - #LA:W010# / Haematologica |  LANDMARK PAPER IN HEMATOLOGY
KW  - Humans
KW  - Cytarabine: therapeutic use
KW  - Cytarabine: administration & dosage
KW  - Leukemia, Myeloid, Acute: genetics
KW  - Leukemia, Myeloid, Acute: drug therapy
KW  - Consolidation Chemotherapy
KW  - Male
KW  - Female
KW  - Middle Aged
KW  - Antimetabolites, Antineoplastic: therapeutic use
KW  - Antimetabolites, Antineoplastic: administration & dosage
KW  - Prognosis
KW  - Adult
KW  - Aged
KW  - Biomarkers, Tumor: genetics
KW  - Treatment Outcome
KW  - Cytarabine (NLM Chemicals)
KW  - Antimetabolites, Antineoplastic (NLM Chemicals)
KW  - Biomarkers, Tumor (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:38832418
DO  - DOI:10.3324/haematol.2024.285624
UR  - https://inrepo02.dkfz.de/record/290595
ER  -